Post-Market Clinical Follow-up Study with ASPIREX®S to Assess the Safety and Effectiveness in the Treatment of DVT

Inclusion criteria

• Acute thrombotic or thromboembolic occlusion (onset of pain < 14 days)
• Age > 18 years
• Written informed consent form

Exclusion criteria

• Patient not suitable for thrombectomy
• Fracture area of broken stents
• Known or suspected allergy to any of the components of the system or to a medicinal product to be administered in connection with the planned procedure
• Persistent vasospasm
• Severe coagulatory disorders
• Patients with thrombophilia
• Aneurysmatically altered vessel segments on target zone or on passage of catheter
• Known or suspected infection, especially of the puncture site or the vessel segment being treated
• Known, unhealed pre-existing mechanical damage to the vessel wall, especially caused by surgical procedures or interventional complications
• Immature or not fully healed dialysis accesses or bypass grafts
• Female subjects of childbearing capacity who are not willing to employ contraceptive measures
• Pregnant or breast feeding subjects
• Subjects who, in the opinion of the investigator, will be inappropriate for inclusion into this study or will not comply with requirements of the study
• Subjects who are lawfully kept in an institution
• Subjects who do not have the mental or physical ability to comply with time schedules and further study procedures
• Current participation in any other clinical study (medicinal, medical device) or within the last 30 days prior to screening